Lab21 Announces Licence Agreement with Ark Therapeutics for Predictive Coronary Heart Disease Diagnostic
The oxLDL test can identify those individuals at the greatest risk of developing CHD, allowing for early preventative action. In addition, the diagnostic is expected to radically alter the clinical diagnosis of heart attacks in the emergency room setting.
Ox-LDL is released from atherosclerotic plaque in increasing amounts as the plaque becomes more unstable, and thus with the increasing likelihood that an area of it will break away from the surface of the blood vessel and obstruct either the coronary artery (causing a heart attack) or a cerebral vessel (causing a stroke). Because oxLDL has a very short half life within the blood, measuring it accurately is difficult. However, the body rapidly produces auto-antibodies and these can be measured by the appropriate antigens.
The oxLDL antibody assay is CE marked and is an ELISA test based upon a novel diagnostic approach with intellectual property surrounding the peptide antigens used. It will be manufactured by Newmarket Laboratories which is part of the Lab21 group of companies.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous